Monza Oncology Day Hospital

Bucharest, Bucharest 13823

0 studies enrolling now · 1 studies all time

What they study most

Adjuvant, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, NSCLC, Stage IB-IIIA, Post-surgical, Uncommon EGFR Mutations

Studies at this site

• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling